PD-166793

• Description :

  PD-166793 is a potent, selective, orally active and wide-broad spectrum inhibitor of MMP, exhibiting nanomolar potency against MMP-2, MMP-3 and MMP-13 (IC50=4, 7, and 8 nM, respectively) and micromolar potency vs MMP-1, -7 and -9 (IC50=6.0, 7.2, and 7.9 μM, respectively) . PD-166793 can attenuate left ventricular remodeling and dysfunction in a rat model of progressive heart failure[1][2][3].

• UNSPSC :

  12352005

• Target :

  MMP

• Type :

  Reference compound

• Related Pathways :

  Metabolic Enzyme/Protease

• Applications :

  Neuroscience-Neuromodulation

• Field of Research :

  Cardiovascular Disease

• Assay Protocol :

  https://www.medchemexpress.com/pd-166793.html

• Purity :

  99.21

• Solubility :

  DMSO : 100 mg/mL (ultrasonic)

• Smiles :

  CC(C)[C@@H](C(O)=O)NS(=O)(C1=CC=C(C2=CC=C(Br)C=C2)C=C1)=O

• Molecular Formula :

  C17H18BrNO4S

• Molecular Weight :

  412.30

• References & Citations :

  [1]O'Brien PM, et, al. Structure-activity relationships and pharmacokinetic analysis for a series of potent, systemically available biphenylsulfonamide matrix metalloproteinase inhibitors. J Med Chem. 2000 Jan 27;43 (2) :156-66.|[2]Kaludercic N, et, al. Inhibiting metalloproteases with PD 166793 in heart failure: impact on cardiac remodeling and beyond. Cardiovasc Ther. Spring 2008;26 (1) :24-37.|[3]Chancey AL, et, al. Effects of matrix metalloproteinase inhibition on ventricular remodeling due to volume overload. Circulation. 2002 Apr 23;105 (16) :1983-8.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• Isoform :

  MMP-1; MMP-13; MMP-2; MMP-3; MMP-7; MMP-9

• CAS Number :

  [199850-67-4]